Report Detail
Global Amyotrophic Lateral Sclerosis (ALS) Market Growth 2019-2024
- RnM2774225 |
- 17 January, 2019 |
- Global |
- 133 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
According to this study, over the next five years the Amyotrophic Lateral Sclerosis (ALS) market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2017. In particular, this report presents the global market share (sales and revenue) of key companies in Amyotrophic Lateral Sclerosis (ALS) business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis (ALS) market by product type, application, key manufacturers and key regions and countries.
This study considers the Amyotrophic Lateral Sclerosis (ALS) value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2013 to 2018, in Section 2.3; and forecast to 2024 in section 11.7.
Riluzole
Edaravone (Radicava)
Other
Segmentation by application: breakdown data from 2013 to 2018, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Drugs Store
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Amyotrophic Lateral Sclerosis (ALS) consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2024.
To understand the structure of Amyotrophic Lateral Sclerosis (ALS) market by identifying its various subsegments.
Focuses on the key global Amyotrophic Lateral Sclerosis (ALS) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyotrophic Lateral Sclerosis (ALS) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Amyotrophic Lateral Sclerosis (ALS) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2018-2023 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Market Report
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption 2013-2023
- 2.1.2 Amyotrophic Lateral Sclerosis (ALS) Consumption CAGR by Region
- 2.2 Amyotrophic Lateral Sclerosis (ALS) Segment by Type
- 2.2.1 Riluzole
- 2.2.2 Edaravone (Radicava)
- 2.2.3 Other
- 2.3 Amyotrophic Lateral Sclerosis (ALS) Consumption by Type
- 2.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Market Share by Type (2013-2018)
- 2.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Type (2013-2018)
- 2.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Type (2013-2018)
- 2.4 Amyotrophic Lateral Sclerosis (ALS) Segment by Application
- 2.4.1 Hospital
- 2.4.2 Drugs Store
- 2.4.3 Other
- 2.5 Amyotrophic Lateral Sclerosis (ALS) Consumption by Application
- 2.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Market Share by Application (2013-2018)
- 2.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Value and Market Share by Application (2013-2018)
- 2.5.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Application (2013-2018)
3 Global Amyotrophic Lateral Sclerosis (ALS) by Players
- 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Players
- 3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Players (2016-2018)
- 3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Players (2016-2018)
- 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Players
- 3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Players (2016-2018)
- 3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Players (2016-2018)
- 3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Players
- 3.4 Global Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Amyotrophic Lateral Sclerosis (ALS) Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 Amyotrophic Lateral Sclerosis (ALS) by Regions
- 4.1 Amyotrophic Lateral Sclerosis (ALS) by Regions
- 4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption by Regions
- 4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Value by Regions
- 4.2 Americas Amyotrophic Lateral Sclerosis (ALS) Consumption Growth
- 4.3 APAC Amyotrophic Lateral Sclerosis (ALS) Consumption Growth
- 4.4 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Growth
- 4.5 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Growth
5 Americas
- 5.1 Americas Amyotrophic Lateral Sclerosis (ALS) Consumption by Countries
- 5.1.1 Americas Amyotrophic Lateral Sclerosis (ALS) Consumption by Countries (2013-2018)
- 5.1.2 Americas Amyotrophic Lateral Sclerosis (ALS) Value by Countries (2013-2018)
- 5.2 Americas Amyotrophic Lateral Sclerosis (ALS) Consumption by Type
- 5.3 Americas Amyotrophic Lateral Sclerosis (ALS) Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Amyotrophic Lateral Sclerosis (ALS) Consumption by Countries
- 6.1.1 APAC Amyotrophic Lateral Sclerosis (ALS) Consumption by Countries (2013-2018)
- 6.1.2 APAC Amyotrophic Lateral Sclerosis (ALS) Value by Countries (2013-2018)
- 6.2 APAC Amyotrophic Lateral Sclerosis (ALS) Consumption by Type
- 6.3 APAC Amyotrophic Lateral Sclerosis (ALS) Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Amyotrophic Lateral Sclerosis (ALS) by Countries
- 7.1.1 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption by Countries (2013-2018)
- 7.1.2 Europe Amyotrophic Lateral Sclerosis (ALS) Value by Countries (2013-2018)
- 7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption by Type
- 7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) by Countries
- 8.1.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption by Countries (2013-2018)
- 8.1.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Value by Countries (2013-2018)
- 8.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption by Type
- 8.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Marketing, Distributors and Customer
- 10.1 Sales Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
- 10.3 Amyotrophic Lateral Sclerosis (ALS) Customer
11 Global Amyotrophic Lateral Sclerosis (ALS) Market Forecast
- 11.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast (2018-2023)
- 11.2 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Regions
- 11.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Regions (2018-2023)
- 11.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Value Forecast by Regions (2018-2023)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Type
- 11.8 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Application
12 Key Players Analysis
- 12.1 Mitsubishi Tanabe Pharma
- 12.1.1 Company Details
- 12.1.2 Amyotrophic Lateral Sclerosis (ALS) Product Offered
- 12.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.1.4 Main Business Overview
- 12.1.5 Mitsubishi Tanabe Pharma News
- 12.2 Sanofi
- 12.2.1 Company Details
- 12.2.2 Amyotrophic Lateral Sclerosis (ALS) Product Offered
- 12.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.2.4 Main Business Overview
- 12.2.5 Sanofi News
- 12.3 Mylan Pharma
- 12.3.1 Company Details
- 12.3.2 Amyotrophic Lateral Sclerosis (ALS) Product Offered
- 12.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.3.4 Main Business Overview
- 12.3.5 Mylan Pharma News
- 12.4 Apotex
- 12.4.1 Company Details
- 12.4.2 Amyotrophic Lateral Sclerosis (ALS) Product Offered
- 12.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.4.4 Main Business Overview
- 12.4.5 Apotex News
- 12.5 Glemark Generics
- 12.5.1 Company Details
- 12.5.2 Amyotrophic Lateral Sclerosis (ALS) Product Offered
- 12.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.5.4 Main Business Overview
- 12.5.5 Glemark Generics News
- 12.6 Covis Pharma
- 12.6.1 Company Details
- 12.6.2 Amyotrophic Lateral Sclerosis (ALS) Product Offered
- 12.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.6.4 Main Business Overview
- 12.6.5 Covis Pharma News
- 12.7 Sun Pharma
- 12.7.1 Company Details
- 12.7.2 Amyotrophic Lateral Sclerosis (ALS) Product Offered
- 12.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.7.4 Main Business Overview
- 12.7.5 Sun Pharma News
- 12.8 Lunan Pharma
- 12.8.1 Company Details
- 12.8.2 Amyotrophic Lateral Sclerosis (ALS) Product Offered
- 12.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.8.4 Main Business Overview
- 12.8.5 Lunan Pharma News
13 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Amyotrophic Lateral Sclerosis (ALS). Industry analysis & Market Report on Amyotrophic Lateral Sclerosis (ALS) is a syndicated market report, published as Global Amyotrophic Lateral Sclerosis (ALS) Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Amyotrophic Lateral Sclerosis (ALS) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
